Summary
Ketanserin, a serotonergic S2-receptor antagonist, was used in a prospective study in nine hypertensive patients with ECG criteria of left ventricular hypertrophy (LVH). Echocardiographic measurement with M mode was made after 1 month of placebo, and after 3, 6, and 12 months of ketanserin treatment as monotherapy at a mean dose of 31 mg bid. Ketanserin treatment decreased mean left ventricular mass by 9.3% at 3 months (not significant), by 15.3% at 6 months (p < 0.008), and by 26.2% at 12 months (p < 0.02), with a tendency towards improvement in left ventricular ejection fraction, which was not statistically significant. The study showed a sustained effect upon regression of LVH in hypertensives, with preservation of left ventricular function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frohlich ED. Cardiac hypertrophy in hypertension. N Engl J Med 1987;317:831–833.
Frohlich ED. Left ventricular hypertrophy as a risk factor. In: Messerly FH, Amadeo C, eds. Cardiology Clinics, Vol. 4. Philadelphia: WB Saunders Co, 1986:137–144.
McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787–792.
Alcocer L, Aspe J, Arce E. Left ventricular hypertrophy in hypertension. Considerations regarding its characteristics and its regression. In: Velasco M, ed. Arterial Hypertension. Amsterdam: Excerpta Medica 1980:240–243.
Dunn FG, Chandraratna P, De Carcalho JGR, et al. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 1977;39:789–795.
Alcocer L, Aspe J. The effect of antihypertensive treatment with methyldopa on left ventricular mass. Royal Society of Medicine, International Congress and Symposium Series 1979;9:93–97.
Frohlich ED. Hypertension and cardiac involvement. In: Sonnenblick EH, Laragh JH, Lesch M, eds. New Frontiers in Cardiovascular Therapy. Elsevier, 1989:117–125.
Vanhoutte P, Amery A, Birkenhager W, et al. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1988;11:111–133.
Fisch CH. Electrocardiography and vectocardiography. In: Braunwald E, ed. Heart Disease. Philadelphia: WB Saunders Co, 1984:195–257.
Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence and mortality in the Framingham study. Ann Intern Med 1969;71:89–105.
Hedner T, Anderson O, Winther K, et al. Are there reasons to believe that the antihypertensive effects of serotonin (S2) antagonists are age-related? J Cardiovasc Pharmacol 1988;12(Suppl 8):S132-S140.
Alcocer L, Cobo C, Calderón B. Comparative trial of ketangerin and methyldopa in the treatment of arterial hypertension. Effect on lipid profile. Am J Hypertens 1989;2:1039.
Reimann IW, Froelich JC. Alpha-adrenolytic effect of ketanserin in man. Lancet 1988;1(8326):703.
Ball SC, Robertson JIS. Is there alpha adrenergic blockade and/or sareteninargic blockade during chronic ketanserin treatment? J Cardiovasc Pharmacol 1985;7(Suppl 7): S210-S122.
Bühler F, Amstein R, Fetkovska N. Serotonin and preactivated platelets in essential hypertension. J Cardiovasc Pharmacol 1987;10(Suppl 3):S32-S34.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cobo, C., Alcocer, L. & Chávez, A. Effects of ketanserin of left ventricular hypertrophy in hypertensive patients. Cardiovasc Drug Ther 4, 73–76 (1990). https://doi.org/10.1007/BF00053431
Issue Date:
DOI: https://doi.org/10.1007/BF00053431